The combination therapy with the cytotoxic T lymphocyte-associated antigen-4 and programmed death 1 antibody-induced asthma in a patient with advanced melanoma

• DOI: 10.4103/jcrt.jcrt_419_21
• Publication Date: 2021-07-09T08:17:46Z
• Authors: Weiran Xu; Bin Lian; Chuanliang Cui; Jun Guo
• Keywords: Combination therapy

The combination of programmed death 1 (PD-1) inhibitors and cytotoxic T lymphocyte-associated antigen-(CTLA-4) have markedly improved the survival melanoma patients. We report case a patient with advanced who developed asthma during anti-PD-1 anti-CTLA-4 therapy. was 57-year-old woman enrolled in clinical trial regarding novel CTLA-4 antibody sintilimab treatment. diagnosed after three cycles Subsequently, she treated corticosteroids, shortcostero β2 agonists, antihistamines. symptoms were relieved 7 days. This is first immunotherapy to best our knowledge. mechanism remains be further explored.